Compound profiles
Peptides
What the laboratory documentation actually shows for each compound, who supplies it, and what it costs per milligram.
How these profiles work
These pages are written from sourcing and laboratory data rather than from clinical literature. For each compound we set out what it is, how the market prices it, and the part most listings leave out: what specifically to check on a certificate of analysis for that molecule, because the failure mode is different every time.
A short cheap peptide fails differently from a fragile copper complex, and both fail differently from a compound whose main risk is being substituted for a cheaper relative. Each profile says which risk applies.
Retatrutide
Triple agonist. The widest price spread we track, and the class where identity confirmation matters most.
TB-500
Sold under two different names for two different molecules, at prices that vary twenty-five fold.
BPC-157
The most widely sold compound on the market, and the one where under-filling beats impurity as the real risk.
GHK-Cu
A copper complex, not a plain peptide. Fragile in transit, and the certificate needs to cover the complex.
NAD+
Not a peptide at all. Handling and storage carry more risk here than the purity report does.
GLP-1 agonists
Semaglutide, tirzepatide and the triple agonists. Related molecules, very different prices.
These compounds are research chemicals and are not approved for human use. Nothing on these pages is medical advice, dosing guidance, or a treatment recommendation. See our medical disclaimer.